Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment
Open Access
- 1 June 2015
- journal article
- research article
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 32, 37-44
Abstract
No abstract availableKeywords
Funding Information
- Boehringer Ingelheim
This publication has 10 references indexed in Scilit:
- Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patientsJournal of Allergy and Clinical Immunology, 2013
- The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo‐controlled, double‐blind trialAllergy, 2012
- Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459European Respiratory Journal, 2012
- A randomized, double‐blind, placebo‐controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthmaClinical & Experimental Allergy, 2011
- Emerging roles of DP and CRTH2 in allergic inflammationTrends in Molecular Medicine, 2006
- Analysis of montelukast in mild persistent asthmatic patients with near-normal lung functionRespiratory Medicine, 2001
- CRTH2, an orphan receptor of T‐helper‐2‐cells, is expressed on basophils and eosinophils and responds to mast cell‐derived factor(s)FEBS Letters, 1999
- Oral Montelukast, Inhaled Beclomethasone, and Placebo for Chronic AsthmaAnnals of Internal Medicine, 1999
- Molecular cloning, chromosome mapping and characterization of the mouse CRTH2 gene, a putative member of the leukocyte chemoattractant receptor familyGene, 1999
- Selective Expression of a Novel Surface Molecule by Human Th2 Cells In VivoThe Journal of Immunology, 1999